TABLE A1. Summary of classifications for hormonal contraceptive methods and intrauterine devices
Condition | Cu-IUD | LNG-IUD | Implants | DMPA | POP | CHCs | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Personal Characteristics And Reproductive History | ||||||||||||
Pregnancy | 4* | 4* | NA* | NA* | NA* | NA* | ||||||
Age | Menarche to <20 years: 2 | Menarche to <20 years: 2 | Menarche to <18 years: 1 | Menarche to <18 years: 2 | Menarche to <18 years: 1 | Menarche to <40 years: 1 | ||||||
≥20 years: 1 | ≥20 years: 1 | 18–45 years: 1 | 18–45 years: 1 | 18–45 years: 1 | ≥40 years: 2 | |||||||
>45 years: 1 | >45 years: 2 | >45 years: 1 | ||||||||||
Parity | ||||||||||||
a. Nulliparous | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
b. Parous | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Breastfeeding | ||||||||||||
a. <21 days postpartum | 2* | 2* | 2* | 4* | ||||||||
b. 21 to <30 days postpartum | ||||||||||||
i. With other risk factors for VTE (e.g., age ≥35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥30 kg/m2, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking) | 2* | 2* | 2* | 3* | ||||||||
ii. Without other risk factors for VTE | 2* | 2* | 2* | 3* | ||||||||
c. 30–42 days postpartum | ||||||||||||
i. With other risk factors for VTE (e.g., age ≥35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥30 kg/m2, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking) | 1* | 1* | 1* | 3* | ||||||||
ii. Without other risk factors for VTE | 1* | 1* | 1* | 2* | ||||||||
d. >42 days postpartum | 1* | 1* | 1* | 2* | ||||||||
Postpartum (nonbreastfeeding women) | ||||||||||||
a. <21 days postpartum | 1 | 1 | 1 | 4 | ||||||||
b. 21–42 days postpartum | ||||||||||||
i. With other risk factors for VTE (e.g., age ≥35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥30 kg/m2, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking) | 1 | 1 | 1 | 3* | ||||||||
ii. Without other risk factors for VTE | 1 | 1 | 1 | 2 | ||||||||
c. >42 days postpartum | 1 | 1 | 1 | 1 | ||||||||
Postpartum (including cesarean delivery) | ||||||||||||
a. <10 minutes after delivery of the placenta | ||||||||||||
i. Breastfeeding | 1* | 2* | ||||||||||
ii. Nonbreastfeeding | 1* | 1* | ||||||||||
b. 10 minutes after delivery of the placenta to <4 weeks (breastfeeding or nonbreastfeeding) | 2* | 2* | ||||||||||
c. ≥4 weeks (breastfeeding or nonbreastfeeding) | 1* | 1* | ||||||||||
d. Postpartum sepsis | 4 | 4 | ||||||||||
Postabortion | ||||||||||||
a. First trimester | 1* | 1* | 1* | 1* | 1* | 1* | ||||||
b. Second trimester | 2* | 2* | 1* | 1* | 1* | 1* | ||||||
c. Immediate postseptic abortion | 4 | 4 | 1* | 1* | 1* | 1* | ||||||
Past ectopic pregnancy | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
History of pelvic surgery (see Postpartum [Including Cesarean Delivery] section) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Smoking | ||||||||||||
a. Age <35 years | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
b. Age ≥35 years | ||||||||||||
i. <15 cigarettes/day | 1 | 1 | 1 | 1 | 1 | 3 | ||||||
ii. ≥15 cigarettes/day | 1 | 1 | 1 | 1 | 1 | 4 | ||||||
Obesity | ||||||||||||
a. BMI ≥30 kg/m2 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
b. Menarche to <18 years and BMI ≥30 kg/m2 | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
History of bariatric surgery This condition is associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Restrictive procedures: decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, or laparoscopic sleeve gastrectomy) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Malabsorptive procedures: decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass or biliopancreatic diversion) | 1 | 1 | 1 | 1 | 3 | COCs: 3 | ||||||
Patch and ring: 1 | ||||||||||||
Cardiovascular Disease | ||||||||||||
Multiple risk factors for atherosclerotic cardiovascular disease (e.g., older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels) | 1 | 2 | 2* | 3* | 2* | 3/4* | ||||||
Hypertension Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg are associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Adequately controlled hypertension | 1* | 1* | 1* | 2* | 1* | 3* | ||||||
b. Elevated blood pressure levels (properly taken measurements) |
||||||||||||
i. Systolic 140–159 mm Hg or diastolic 90–99 mm Hg | 1* | 1* | 1* | 2* | 1* | 3* | ||||||
ii. Systolic ≥160 mm Hg or diastolic ≥100 mm Hg | 1* | 2* | 2* | 3* | 2* | 4* | ||||||
c. Vascular disease | 1* | 2* | 2* | 3* | 2* | 4* | ||||||
History of high blood pressure during pregnancy (when current blood pressure is measurable and normal) | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
Deep venous thrombosis/ Pulmonary embolism |
||||||||||||
a. History of DVT/PE, not receiving anticoagulant therapy | ||||||||||||
i. Higher risk for recurrent DVT/PE (one or more risk factors) | 1 | 2 | 2 | 2 | 2 | 4 | ||||||
• History of estrogen-associated DVT/PE • Pregnancy-associated DVT/PE • Idiopathic DVT/PE • Known thrombophilia, including antiphospholipid syndrome • Active cancer (metastatic, receiving therapy, or within 6 months after clinical remission), excluding nonmelanoma skin cancer • History of recurrent DVT/PE |
||||||||||||
ii. Lower risk for recurrent DVT/PE (no risk factors) | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
b. Acute DVT/PE | 2 | 2 | 2 | 2 | 2 | 4 | ||||||
c. DVT/PE and established anticoagulant therapy for at least 3 months | ||||||||||||
i. Higher risk for recurrent DVT/PE (one or more risk factors) | 2 | 2 | 2 | 2 | 2 | 4* | ||||||
• Known thrombophilia, including antiphospholipid syndrome • Active cancer (metastatic, receiving therapy, or within 6 months after clinical remission), excluding nonmelanoma skin cancer • History of recurrent DVT/PE |
||||||||||||
ii. Lower risk for recurrent DVT/PE (no risk factors) | 2 | 2 | 2 | 2 | 2 | 3* | ||||||
d. Family history (first-degree relatives) | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
e. Major surgery | ||||||||||||
i. With prolonged immobilization | 1 | 2 | 2 | 2 | 2 | 4 | ||||||
ii. Without prolonged immobilization | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
f. Minor surgery without immobilization | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Known thrombogenic mutations (e.g., factor V Leiden; prothrombin mutation; and protein S, protein C, and antithrombin deficiencies) This condition is associated with increased risk for adverse health events as a result of pregnancy. |
1* | 2* | 2* | 2* | 2* | 4* | ||||||
Superficial venous disorders | ||||||||||||
a. Varicose veins | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Superficial venous thrombosis (acute or history) | 1 | 1 | 1 | 1 | 1 | 3* | ||||||
Current and history of ischemic heart disease This condition is associated with increased risk for adverse health events as a result of pregnancy. |
Initiation | Continuation | Initiation | Continuation | Initiation | Continuation | ||||||
1 | 2 | 3 | 2 | 3 | 3 | 2 | 3 | 4 | ||||
Stroke (history of cerebrovascular accident) This condition is associated with increased risk for adverse health events as a result of pregnancy. |
Initiation | Continuation | Initiation | Continuation | ||||||||
1 | 2 | 2 | 3 | 3 | 2 | 3 | 4 | |||||
Valvular heart disease Complicated valvular heart disease is associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Uncomplicated | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
b. Complicated (pulmonary hypertension, risk for atrial fibrillation, or history of subacute bacterial endocarditis) | 1 | 1 | 1 | 1 | 1 | 4 | ||||||
Peripartum cardiomyopathy This condition is associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Normal or mildly impaired cardiac function (New York Heart Association Functional Class I or II: patients with no limitation of activities or patients with slight, mild limitation of activity) (2) | ||||||||||||
i. <6 months | 2 | 2 | 1 | 1 | 1 | 4 | ||||||
ii. ≥6 months | 2 | 2 | 1 | 1 | 1 | 3 | ||||||
b. Moderately or severely impaired cardiac function (New York Heart Association Functional Class III or IV: patients with marked limitation of activity or patients who should be at complete rest) (2). | 2 | 2 | 2 | 2 | 2 | 4 | ||||||
Rheumatic Diseases | ||||||||||||
Systemic lupus erythematosus This condition is associated with increased risk for adverse health events as a result of pregnancy. |
Initiation | Continuation | Initiation | Continuation | ||||||||
a. Positive (or unknown) antiphospholipid antibodies | 1* | 1* | 3* | 3* | 3* | 3* | 3* | 4* | ||||
b. Severe thrombocytopenia | 3* | 2* | 2* | 2* | 3* | 2* | 2* | 2* | ||||
c. Immunosuppressive therapy | 2* | 1* | 2* | 2* | 2* | 2* | 2* | 2* | ||||
d. None of the above | 1* | 1* | 2* | 2* | 2* | 2* | 2* | 2* | ||||
Rheumatoid arthritis | Initiation | Continuation | Initiation | Continuation | ||||||||
a. Receiving immunosuppressive therapy | 2 | 1 | 2 | 1 | 1 | 2/3* | 1 | 2 | ||||
b. Not receiving immunosuppressive therapy | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
Neurologic Conditions | ||||||||||||
Headaches | ||||||||||||
a. Nonmigraine (mild or severe) | 1 | 1 | 1 | 1 | 1 | 1* | ||||||
b. Migraine | ||||||||||||
i. Without aura (This category of migraine includes menstrual migraine.) | 1 | 1 | 1 | 1 | 1 | 2* | ||||||
ii. With aura | 1 | 1 | 1 | 1 | 1 | 4* | ||||||
Epilepsy This condition is associated with increased risk for adverse health events as a result of pregnancy. |
1 | 1 | 1* | 1* | 1* | 1* | ||||||
Multiple sclerosis | ||||||||||||
a. With prolonged immobility | 1 | 1 | 1 | 2 | 1 | 3 | ||||||
b. Without prolonged immobility | 1 | 1 | 1 | 2 | 1 | 1 | ||||||
Depressive Disorders | ||||||||||||
Depressive disorders | 1* | 1* | 1* | 1* | 1* | 1* | ||||||
Reproductive Tract Infections and Disorders | ||||||||||||
Vaginal bleeding patterns | Initiation | Continuation | ||||||||||
a. Irregular pattern without heavy bleeding | 1 | 1 | 1 | 2 | 2 | 2 | 1 | |||||
b. Heavy or prolonged bleeding (includes regular and irregular patterns) | 2* | 1* | 2* | 2* | 2* | 2* | 1* | |||||
Unexplained vaginal bleeding (suspicious for serious condition) before evaluation |
Initiation | Continuation | Initiation | Continuation | ||||||||
4* | 2* | 4* | 2* | 3* | 3* | 2* | 2* | |||||
Endometriosis | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Benign ovarian tumors (including cysts) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Severe dysmenorrhea | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Gestational trophoblastic disease This condition is associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Suspected gestational trophoblastic disease (immediate postevacuation) | ||||||||||||
i. Uterine size first trimester | 1* | 1* | 1* | 1* | 1* | 1* | ||||||
ii. Uterine size second trimester | 2* | 2* | 1* | 1* | 1* | 1* | ||||||
b. Confirmed gestational trophoblastic disease (after initial evacuation and during monitoring) | Initiation | Continuation | Initiation | Continuation | ||||||||
i. Undetectable/non-pregnant β-hCG levels | 1* | 1* | 1* | 1* | 1* | 1* | 1* | 1* | ||||
ii. Decreasing β-hCG levels | 2* | 1* | 2* | 1* | 1* | 1* | 1* | 1* | ||||
iii. Persistently elevated β-hCG levels or malignant disease, with no evidence or suspicion of intrauterine disease | 2* | 1* | 2* | 1* | 1* | 1* | 1* | 1* | ||||
iv. Persistently elevated β-hCG levels or malignant disease, with evidence or suspicion of intrauterine disease | 4* | 2* | 4* | 2* | 1* | 1* | 1* | 1* | ||||
Cervical ectropion | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Cervical intraepithelial neoplasia | 1 | 2 | 2 | 2 | 1 | 2 | ||||||
Cervical cancer (awaiting treatment) | Initiation | Continuation | Initiation | Continuation | ||||||||
4 | 2 | 4 | 2 | 2 | 2 | 1 | 2 | |||||
Breast disease Breast cancer is associated with increased risk of adverse health events as a result of pregnancy. |
||||||||||||
a. Undiagnosed mass | 1 | 2 | 2* | 2* | 2* | 2* | ||||||
b. Benign breast disease | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
c. Family history of cancer | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
d. Breast cancer | ||||||||||||
i. Current | 1 | 4 | 4 | 4 | 4 | 4 | ||||||
ii. Past and no evidence of current disease for 5 years | 1 | 3 | 3 | 3 | 3 | 3 | ||||||
Endometrial hyperplasia | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Endometrial cancer This condition is associated with increased risk for adverse health events as a result of pregnancy. |
Initiation | Continuation | Initiation | Continuation | ||||||||
4 | 2 | 4 | 2 | 1 | 1 | 1 | 1 | |||||
Ovarian cancer This condition is associated with increased risk for adverse health events as a result of pregnancy. |
1 | 1 | 1 | 1 | 1 | 1 | ||||||
Uterine fibroids | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
Anatomical abnormalities | ||||||||||||
a. Distorted uterine cavity (any congenital or acquired uterine abnormality distorting the uterine cavity in a manner that is incompatible with IUD insertion) | 4 | 4 | ||||||||||
b. Other abnormalities (including cervical stenosis or cervical lacerations) not distorting the uterine cavity or interfering with IUD insertion | 2 | 2 | ||||||||||
Pelvic inflammatory disease | ||||||||||||
a. Past PID | Initiation | Continuation | Initiation | Continuation | ||||||||
i. With subsequent pregnancy | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||
ii. Without subsequent pregnancy | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||
b. Current PID | 4 | 2* | 4 | 2* | 1 | 1 | 1 | 1 | ||||
Sexually transmitted diseases | Initiation | Continuation | Initiation | Continuation | ||||||||
a. Current purulent cervicitis or chlamydial infection or gonococcal infection | 4 | 2* | 4 | 2* | 1 | 1 | 1 | 1 | ||||
b. Vaginitis (including Trichomonas vaginalis and bacterial vaginosis) | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||
c. Other factors related to STDs | 2* | 2 | 2* | 2 | 1 | 1 | 1 | 1 | ||||
HIV | ||||||||||||
Initiation | Continuation | Initiation | Continuation | |||||||||
High risk for HIV | 1* | 1* | 1* | 1* | 1 | 1 | 1 | 1 | ||||
HIV infection For women with HIV infection who are not clinically well or not receiving ARV therapy, this condition is associated with increased risk for adverse health events as a result of pregnancy. | — | — | — | — | 1* | 1* | 1* | 1* | ||||
a. Clinically well receiving ARV therapy | 1 | 1 | 1 | 1 | ||||||||
b. Not clinically well or not receiving ARV therapy | 2 | 1 | 2 | 1 | ||||||||
Other Infections | ||||||||||||
Schistosomiasis Schistosomiasis with fibrosis of the liver is associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Uncomplicated | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Fibrosis of the liver (if severe, see Cirrhosis) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Tuberculosis This condition is associated with increased risk for adverse health events as a result of pregnancy. |
Initiation | Continuation | Initiation | Continuation | ||||||||
a. Nonpelvic | 1 | 1 | 1 | 1 | 1* | 1* | 1* | 1* | ||||
b. Pelvic | 4 | 3 | 4 | 3 | 1* | 1* | 1* | 1* | ||||
Malaria | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Endocrine Conditions | ||||||||||||
Diabetes Insulin-dependent diabetes; diabetes with nephropathy, retinopathy, or neuropathy; diabetes with other vascular disease; or diabetes of >20 years’ duration are associated with increased risk of adverse health events as a result of pregnancy. |
||||||||||||
a. History of gestational disease | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Nonvascular disease | ||||||||||||
i. Non-insulin dependent | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
ii. Insulin dependent | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
c. Nephropathy/retinopathy/neuropathy | 1 | 2 | 2 | 3 | 2 | 3/4* | ||||||
d. Other vascular disease or diabetes of >20 years’ duration | 1 | 2 | 2 | 3 | 2 | 3/4* | ||||||
Thyroid disorders | ||||||||||||
a. Simple goiter | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Hyperthyroid | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
c. Hypothyroid | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Gastrointestinal Conditions | ||||||||||||
Inflammatory bowel disease (ulcerative colitis or Crohn’s disease) | 1 | 1 | 1 | 2 | 2 | 2/3* | ||||||
Gallbladder disease | ||||||||||||
a. Symptomatic | ||||||||||||
i. Treated by cholecystectomy | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
ii. Medically treated | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
iii. Current | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
b. Asymptomatic | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
History of cholestasis | ||||||||||||
a. Pregnancy related | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
b. Past COC related | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
Viral hepatitis | Initiation | Continuation | ||||||||||
a. Acute or flare | 1 | 1 | 1 | 1 | 1 | 3/4* | 2 | |||||
b. Carrier | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
c. Chronic | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Cirrhosis Severe cirrhosis is associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Mild (compensated) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Severe (decompensated) | 1 | 3 | 3 | 3 | 3 | 4 | ||||||
Liver tumors Hepatocellular adenoma and malignant liver tumors are associated with increased risk for adverse health events as a result of pregnancy. |
||||||||||||
a. Benign | ||||||||||||
i. Focal nodular hyperplasia | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
ii. Hepatocellular adenoma | 1 | 3 | 3 | 3 | 3 | 4 | ||||||
b. Malignant (hepatoma) | 1 | 3 | 3 | 3 | 3 | 4 | ||||||
Respiratory Conditions | ||||||||||||
Cystic fibrosis This condition is associated with increased risk for adverse health events as a result of pregnancy. |
1* | 1* | 1* | 2* | 1* | 1* | ||||||
Anemias | ||||||||||||
Thalassemia | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Sickle cell disease This condition is associated with increased risk for adverse health events as a result of pregnancy. |
2 | 1 | 1 | 1 | 1 | 2 | ||||||
Iron-deficiency anemia | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Solid Organ Transplantation | ||||||||||||
Solid organ transplantation This condition is associated with increased risk for adverse health events as a result of pregnancy. |
Initiation | Continuation | Initiation | Continuation | ||||||||
a. Complicated: graft failure (acute or chronic), rejection, or cardiac allograft vasculopathy | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 4 | ||||
b. Uncomplicated | 2 | 2 | 2 | 2 | 2 | 2* | ||||||
Drug Interactions | ||||||||||||
Antiretrovirals used for prevention (PrEP) or treatment of HIV | Initiation | Continuation | Initiation | Continuation | ||||||||
a. Nucleoside reverse transcriptase inhibitors (NRTIs) | ||||||||||||
i. Tenofovir (TDF) (Used for prevention (PrEP) or treatment) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
ii. Emtricitabine (FTC) (Used for prevention (PrEP) or treatment) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
iii. Zidovudine (AZT) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
iv. Lamivudine (3TC) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
v. Didanosine (DDI) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
vi. Abacavir (ABC) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
vii. Stavudine (D4T) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
b. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) | ||||||||||||
i. Efavirenz (EFV) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
ii. Etravirine (ETR) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
iii. Nevirapine (NVP) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
iv. Rilpivirine (RPV) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
c. Ritonavir-boosted protease inhibitors | ||||||||||||
i. Ritonavir-boosted atazanavir (ATV/r) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
ii. Ritonavir-boosted darunavir (DRV/r) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
iii. Ritonavir-boosted fosemprenavir (FPV/r) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
iv. Ritonavir-boosted lopinavir (LPV/r) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
v. Ritonavir-boosted saquinavir (SQV/r) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
vi. Ritonavir-boosted tipranavir (TPV/r) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
d. Protease inhibitors without ritonavir | ||||||||||||
i. Atazanavir (ATV) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 2* | ||||
ii. Fosamprenavir (FPV) | 1/2* | 1* | 1/2* | 1* | 2* | 2* | 2* | 3* | ||||
iii. Indinavir (IDV) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
iv. Nelfinavir (NFV) | 1/2* | 1* | 1/2* | 1* | 2* | 1* | 2* | 2* | ||||
e. CCR5 co-receptor antagonists | ||||||||||||
i. Maraviroc (MVC) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
f. HIV integrase strand transfer inhibitors | ||||||||||||
i. Raltegravir (RAL) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
ii. Dolutegravir (DTG) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
iii. Elvitegravir (EVG) | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
g. Fusion inhibitors | ||||||||||||
i. Enfuvirtide | 1/2* | 1* | 1/2* | 1* | 1 | 1 | 1 | 1 | ||||
Anticonvulsant therapy | ||||||||||||
a. Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine) | 1 | 1 | 2* | 1* | 3* | 3* | ||||||
b. Lamotrigine | 1 | 1 | 1 | 1 | 1 | 3* | ||||||
Antimicrobial therapy | ||||||||||||
a. Broad-spectrum antibiotics | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
b. Antifungals | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
c. Antiparasitics | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
d. Rifampin or rifabutin therapy | 1 | 1 | 2* | 1* | 3* | 3* | ||||||
Psychotropic medications | ||||||||||||
a. SSRIs | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
St. John’s wort | 1 | 1 | 2 | 1 | 2 | 2 |
Abbreviations: BMI = body mass index; COC = combined oral contraceptive; Cu-IUD = copper-containing IUD; DMPA = depot medroxyprogesterone acetate; DVT = deep venous thrombosis; hCG = human chorionic gonadotropin; HDL = high-density lipoprotein; HIV = human immunodeficiency virus.; IUD = intrauterine device; LDL = low-density lipoprotein; LNG-IUD = levonorgestrel-releasing IUD; NA = not applicable; PE = pulmonary embolism; PID = pelvic inflammatory disease; POP = progestin-only pill; SSRI = selective serotonin reuptake inhibitor; STD = sexually transmitted disease.
*Consult the respective appendix for each contraceptive method in the 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (1) for clarifications to the numeric categories.